Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Mar 30;324(7340):768.
doi: 10.1136/bmj.324.7340.768.

Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema

Affiliations
Clinical Trial

Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema

K S Thomas et al. BMJ. .

Abstract

Objective: To determine whether a three day burst of a potent corticosteroid is more effective than a mild preparation used for seven days in children with mild or moderate atopic eczema.

Design: Randomised, double blind, parallel group study of 18 weeks' duration.

Setting: 13 general practices and a teaching hospital in the Nottingham area.

Participants: 174 children with mild or moderate atopic eczema recruited from general practices and 33 from a hospital outpatient clinic.

Interventions: 0.1% betamethasone valerate applied for three days followed by the base ointment for four days versus 1% hydrocortisone applied for seven days.

Main outcome measures: Primary outcomes were total number of scratch-free days and number of relapses. Secondary outcomes were median duration of relapses, number of undisturbed nights, disease severity (six area, six sign atopic dermatitis severity scale), scores on two quality of life measures (children's life quality index and dermatitis family impact questionnaire), and number of patients in whom treatment failed in each arm.

Results: No differences were found between the two groups. This was consistent for all outcomes. The median number of scratch-free days was 118.0 for the mild group and 117.5 for the potent group (difference 0.5, 95% confidence interval -2.0 to 4.0, P=0.53). The median number of relapses for both groups was 1.0. Both groups showed clinically important improvements in disease severity and quality of life compared with baseline.

Conclusion: A short burst of a potent topical corticosteroid is just as effective as prolonged use of a milder preparation for controlling mild or moderate atopic eczema in children.

PubMed Disclaimer

Figures

Figure
Figure
Flow of participants through trial

References

    1. Emerson RM, Williams HC, Allen BR. Severity distribution of atopic dermatitis in the community and its relationship to secondary referral. Br J Dermatol. 1998;139:73–76. - PubMed
    1. Williams HC, Wuthrich B. The natural history of atopic dermatitis. In: Williams HC, editor. Atopic dermatitis. Cambridge: Cambridge University Press; 2000. , 41-59.
    1. McHenry P, Williams HC, Bingham EA. Treatment of atopic eczema. BMJ. 1995;310:843–847. - PMC - PubMed
    1. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931–936. - PubMed
    1. Fisher G. Compliance problems in paediatric atopic eczema. Aust J Dermatol. 1996;37:10–3S. - PubMed

Publication types

MeSH terms